Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
No evidence seen to support GLP-1 receptor agonist exenatide as disease-modifying treatment for Parkinson disease. HealthDay News — The glucagon-like peptide-1 receptor agonist exenatide does ...
Lithium Argentina AG is a resource and materials company that engages in the production of lithium carbonate for lithium-ion batteries and electric vehicles. Its projects include: Cauchari-Olaroz ...
The discovery of leptin and gut hormones as major neuroendocrine regulators of bodyweight is leading the way to the development of attractive therapeutic approaches to the long-term manipulation ...
Hosted on MSN1mon
Study Finds Exenatide Not Beneficial for Parkinson DiseaseFRIDAY, Feb. 7, 2025 (HealthDay News) -- The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity, according to a study published ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback